Over the past few decades, two significant advancements have emerged in our surgical approaches. One is a combination of technical and organizational elements known as enhanced recovery after surgery (ERAS), while the other is a technological innovation- robotic surgery. Both innovations aim to reduce surgical stress and enhance postoperative results, with robotic surgery achieving this through minimal invasiveness and ERAS through comprehensive medical and surgical perioperative measures. Rather than choosing between the two, a more prudent approach might involve utilizing them synergistically (1).

Enhanced Recovery After Surgery (ERAS) protocols, have been introduced as a quality enhancement effort, yielding positive clinical outcomes for patients and economic advantages for the healthcare system (2). Within the gynaecological domain, the ERAS protocol has been widely adopted for both patients with gynaecological cancers and those with benign conditions (3). While the majority of research on ERAS in gynaecological surgery has concentrated on open procedures, it has been established that ERAS is safe and viable even in minimally invasive surgery (MIS) including robotic assisted procedures. In terms of patient outcomes, MIS has demonstrated a reduction in blood loss, required analgesia, time for the return of bowel function, hospital stay, and the duration until patients resume normal activities (4). In this study we aimed to investigate how implementation of the ERAS program in patients undergoing robotic hysterectomy for benign indications affects the length of hospital stay (LOHS) in comparison with conventional management. We also aimed to compare postoperative complications within 30 days after surgery and quality of life.